A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution-Reference-Cited by-同舟云学术

A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution

Published:2016-05-10 Issue:27 Volume:7 Page:41242-41250
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Huang Jia-Jia¹²,Xia Yi¹²,Wang Yu¹²,Liu Pan-Pan¹²,Bi Xi-Wen¹²,Sun Peng¹²,Lin Tong-Yu¹²,Jiang Wen-Qi¹²,Li Zhi-Ming¹²

Affiliation:

1. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China

2. Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual Oncological Challenges: Management of Simultaneous Lung Adenocarcinoma and Primary Cardiac Lymphoma;Cureus;2024-06-28

2. How to improve RCHOP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of 21 randomized controlled trials;Annals of Hematology;2024-01-08

3. MYC overexpression but not MYC/BCL2 double expression predicts survival in bulky mass diffuse large B‐cell lymphoma patients;Cancer Medicine;2023-08-28

4. Prognostic factors for diffuse large B-cell lymphoma: clinical and biological factors in the rituximab era;Experimental Hematology;2023-06

5. A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma;Leukemia & Lymphoma;2022-11-02